ASCO’s 2024 Cannabis Guidelines for Cancer Symptom Management
Introduction The May 2024 guideline published by ASCO provides a detailed analysis of the evidence for cannabis and cannabinoid use […]
Provider Regulation
Navigating State-by-State Cannabis Labeling Requirements: Insights for Clinicians (Kruger et al., April 2022)
Introduction The study by Kruger, Korach, and Kruger in Cannabis and Cannabinoid Research (April 2022) delves into the fragmented landscape
Cannabis Marketing Compliance: A Look at State Regulations—Hybrid Marketing Co., 2024
Introduction: The 2024 report by Hybrid Marketing Co. offers a comprehensive breakdown of state-by-state cannabis advertising regulations. These rules are
Elevating Cannabis Safety: cGMP Compliance for Consistent Testing – Insights from Cannabis Science & Technology, 2024
Introduction The variability in cannabis testing results poses a critical challenge for healthcare providers prescribing or recommending cannabis products. A
Colorado’s Cannabis Industry: Evaluating a Decade of Legalization
Published: September 23, 2024, by The Times Introduction Since Colorado’s groundbreaking move to legalize recreational cannabis in 2014, the industry
IRS Section 280E and Cannabis: Legal and Economic Insights by University of Michigan Scholars (2019)
Intro: Douglas A. Kahn and Howard Bromberg from the University of Michigan Law School critically examine IRS Section 280E’s implications
Clinical Trial Insights: Ketamine’s Expanding Role in Psychiatry (Peyrovian et al., 2020)
Introduction: Peyrovian et al.’s 2020 review in the Journal of Psychiatric Research summarizes registered clinical trials evaluating ketamine for psychiatric
Ketamine Pilot Study for Late-Life Depression: Early Insights (Lenze, ClinicalTrials.gov, 2020)
Introduction: Dr. Eric Lenze’s 2020 pilot study investigates ketamine’s safety and efficacy in older adults with treatment-resistant depression (TRD). This
Esketamine: A Paradigm Shift in TRD Treatment (Kim et al., NEJM, 2019)
Introduction: Kim and colleagues’ 2019 article in The New England Journal of Medicine reviews the groundbreaking approval of esketamine as
Esketamine: Insights into a Novel NMDA Antagonist for TRD (Hough, FDA, 2019)
Introduction: Dr. David Hough’s 2019 FDA report presents a comprehensive overview of esketamine, its development, and its approval as a